Gerresheimer Faces Intensified Scrutiny Over Accounting Practices

The regulatory pressure on packaging specialist Gerresheimer is mounting. Germany's Federal Financial Supervisory Authority, BaFin, is significantly expanding its audit of the company's financial statements, indicating that initial findings have not satisfied the regulator. The investigation is now focusing on revenue recognition practices that could potentially lead to substantial corrections.

Broadening Audit Scope

Authorities are conducting a detailed examination of the group's financial statements for 2023/24 and the half-year report for 2024/25. A key area of inquiry is the company's use of "bill-and-hold" arrangements. This accounting method involves recognizing revenue for goods that have been invoiced but are still held in the company's own warehouse, not yet delivered to the customer. The probe is assessing whether this revenue was booked prematurely.

The audit has been widened to include several other critical items. These encompass the valuation of lease liabilities, capitalized development costs, and the appropriateness of impairment charges already taken. The completeness of the company's risk reporting is also under review.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Operational and Political Headwinds Converge

This regulatory uncertainty compounds existing challenges for the group. Soaring production costs are heavily burdening its energy-intensive operations. Energy prices, for instance, climbed by 7.2 percent in March, contributing to broader inflationary pressures.

Simultaneously, political developments pose a separate threat. An expert commission has recommended sweeping savings in the healthcare sector of up to €19 billion. Deep cuts of this magnitude are expected to noticeably dampen the ordering behavior of pharmaceutical companies, which are Gerresheimer's most important customers.

Market Reaction and Outlook

The combination of operational strain and balance sheet risks has left a pronounced mark on the company's market valuation. Gerresheimer shares closed at €19.40 on Monday. Over a twelve-month period, the stock has now declined by 72.40 percent.

Market observers note that the risk of material corrections to the financial statements will continue to weigh on the share price until BaFin concludes its investigation. A sustained technical stabilization in the stock's chart is seen as contingent on clarity regarding the true earnings situation of past fiscal years.

Ad

Gerresheimer Stock: New Analysis - 31 March

Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Gerresheimer analysis...

DE000A0LD6E6 | GERRESHEIMER | boerse | 69033661 |